MCAS gets misdiagnosed as IBS for a straightforward reason: gastroenterologists are trained to evaluate the gut, and the gut symptoms of MCAS look identical to IBS. Abdominal pain, bloating, diarrhea, nausea, and food-triggered flares all fit neatly within the Rome IV criteria. The IBS label gets applied, and the non-GI symptoms that would point toward mast cell activation, the flushing, hives, brain fog, tachycardia, and environmental sensitivities, either get ignored, attributed to anxiety, or sent to other specialists who evaluate them in isolation. The result is a patient with a multi-system immune disorder being treated for a single-organ functional condition.
Why do GI doctors miss MCAS?
The miss happens because of how gastroenterology training and clinical workflow are structured, not because individual doctors are careless. GI specialists evaluate GI symptoms. Their diagnostic algorithms start with Rome IV criteria for functional disorders, screen for red flags (celiac, IBD, colorectal cancer), and apply the IBS label when those screens are negative. Mast cell mediator testing is not part of this algorithm. There is no prompt in the Rome IV criteria to ask about skin flushing, hives, or heart rate changes. There is no recommendation to check serum tryptase or urinary histamine metabolites as part of the IBS workup.
The problem is compounded by subspecialization. A patient with MCAS may see a gastroenterologist for abdominal pain, a dermatologist for unexplained rashes, a cardiologist for palpitations, and a neurologist for brain fog. Each specialist evaluates and treats within their domain. Without someone synthesizing the full clinical picture across systems, the pattern of mast cell activation remains invisible. The GI piece gets called IBS. The skin piece gets called chronic urticaria. The cardiology piece gets attributed to anxiety. The neurology piece gets labeled as migraine or stress-related cognitive complaints.
The diagnostic criteria controversy
MCAS diagnosis is complicated by the absence of a single, universally accepted set of diagnostic criteria. Three major frameworks exist, and they differ significantly in their requirements.
- The Valent criteria (2012) are the most restrictive. They require episodic symptoms in two or more organ systems, documented elevation of a validated mast cell mediator (typically serum tryptase rise of 20% plus 2 ng/mL above baseline during an episode), and response to mast cell-targeted therapy. These criteria are endorsed by many academic allergists.
- The Molderings criteria (2011) are broader. They accept a wider range of mast cell mediators as evidence and place more weight on clinical presentation. This framework recognizes that tryptase may not be elevated in all MCAS patients, especially those whose mast cells release other mediators preferentially.
- The Afrin criteria (2020) are the most inclusive. They emphasize the multi-system symptom pattern, accept response to antihistamines or mast cell stabilizers as supporting evidence, and allow for the possibility that current laboratory tests are insufficiently sensitive to capture all forms of mast cell activation.
This disagreement among experts creates real problems for patients. A patient who meets the Afrin criteria but not the Valent criteria may receive an MCAS diagnosis from one specialist and have it rejected by another. Some clinicians view the broader criteria as too permissive, potentially capturing patients whose symptoms have other causes. Others argue that the strict criteria miss genuine MCAS cases because the available lab tests are not sensitive enough. For patients caught in the middle, the diagnostic uncertainty means that getting evaluated often depends on which expert their doctor trained under.
Multi-system vs single-system presentation
The defining feature of MCAS is that it affects multiple organ systems. This is also what makes it hard to diagnose from within any single specialty. A patient whose mast cells primarily degranulate in the GI tract may present to a gastroenterologist with symptoms that are functionally identical to IBS-D or IBS-M. If the clinician does not ask about or the patient does not volunteer non-GI symptoms, the multi-system pattern remains hidden.
Patients sometimes do not connect their own symptoms. A person with chronic bloating may not think to mention to their GI doctor that they also get flushed after hot showers, develop hives when stressed, or feel their heart race after eating certain foods. These symptoms may have been present for years and may have been evaluated separately by other doctors. The patient has no reason to think their skin symptoms and gut symptoms are related unless someone tells them that a single condition can explain both.
âšī¸Before your GI appointment, write down all your symptoms across all body systems, including how often they occur and what triggers them. Dermatologic, cardiovascular, neurologic, and respiratory symptoms are relevant to your GI evaluation if MCAS is a possibility. Presenting the full picture gives your doctor the best chance of recognizing the pattern.
The "difficult patient" label
Patients with undiagnosed MCAS frequently accumulate a clinical reputation that works against them. They present with vague, fluctuating, multi-system complaints. Their symptoms are hard to reproduce in a clinical setting because MCAS flares are episodic and unpredictable. Standard tests come back normal between episodes. They may have seen five, ten, or more specialists without a unifying diagnosis. They have thick charts and long problem lists. In a time-pressured clinical environment, this pattern can lead to implicit or explicit characterization as a "difficult patient" or to the assumption that the symptoms are psychosomatic.
Research by Jennings and colleagues (2018) documents that patients with multi-system symptoms lacking a clear diagnosis experience longer diagnostic delays, higher rates of psychological misattribution, and more negative interactions with the healthcare system. This pattern is not unique to MCAS, but MCAS patients are particularly vulnerable because their condition is episodic, their test results fluctuate, and some clinicians do not consider MCAS a well-established diagnosis. The result is a feedback loop: the longer a patient goes undiagnosed, the more likely they are to be labeled as anxious or somatizing, which makes clinicians less likely to pursue further organic evaluation.
Evidence for mast cell involvement in IBS
Independent of the MCAS diagnostic debate, there is solid evidence that mast cells play a role in IBS pathophysiology. Barbara and colleagues published a landmark study in 2004 showing that IBS patients had increased mast cell density in colonic biopsies compared to healthy controls, and that mast cells in IBS patients were located closer to nerve endings. The proximity of activated mast cells to enteric nerves correlated with abdominal pain severity. This finding has been replicated in multiple studies. It suggests that some IBS patients may have localized mast cell activation in the gut, even if they do not meet full MCAS criteria for multi-system disease. For these patients, mast cell-targeted therapies (H1/H2 antihistamines, cromolyn sodium) may improve GI symptoms even without a formal MCAS diagnosis.
What to do if you suspect MCAS is being missed
If your IBS diagnosis does not fully explain your symptoms, particularly if you have non-GI manifestations that have been evaluated separately or dismissed, there are practical steps to pursue.
- Document your complete symptom pattern across all organ systems, including skin, cardiovascular, neurologic, and respiratory symptoms, with triggers and timing.
- Ask your gastroenterologist directly whether MCAS could be contributing to your GI symptoms, especially if standard IBS treatments have not worked.
- Request a referral to an allergist or immunologist experienced in mast cell disorders if your GI doctor is unable to evaluate for MCAS.
- Ask about serum tryptase testing during a symptomatic episode and 24-hour urinary N-methylhistamine or prostaglandin D2 metabolite testing.
- Consider an empiric trial of H1 and H2 antihistamines (cetirizine plus famotidine) under medical supervision. Symptom improvement supports mast cell involvement.
â ī¸The lack of consensus on MCAS criteria does not mean the condition is not real. It means the field is still refining diagnostic standards. If your symptoms fit the clinical pattern and you respond to mast cell-targeted treatments, that clinical response is meaningful information regardless of which diagnostic framework your doctor follows.
Frequently Asked Questions
How common is it for MCAS to be misdiagnosed as IBS?
No large-scale studies have measured this directly. However, given that increased mast cell activation has been documented in IBS patient biopsies and that MCAS diagnostic testing is not part of standard IBS workups, misclassification is likely underrecognized. The prevalence of MCAS itself is estimated at 1-17% of the general population depending on which diagnostic criteria are applied.
Why is MCAS controversial among some doctors?
The controversy centers on diagnostic criteria. Some physicians accept only the strict Valent criteria (requiring documented tryptase elevation), while others apply broader clinical frameworks. The disagreement is not about whether mast cells can become hyperactive, which is established, but about how to define the threshold for diagnosis. This means your experience may vary significantly depending on the clinician.
Can stress cause both IBS and MCAS flares?
Yes. Psychological stress is a documented trigger for both IBS symptom flares and mast cell degranulation. In MCAS, stress activates mast cells through corticotropin-releasing hormone (CRH) and other neuroendocrine pathways. This shared trigger can make the two conditions harder to distinguish clinically and may contribute to symptoms being attributed to anxiety rather than mast cell activation.
Will my gastroenterologist know about MCAS?
Awareness varies. Many gastroenterologists are familiar with the research on mast cells in IBS but may not routinely evaluate for MCAS as a distinct diagnosis. Some may be skeptical of MCAS as a clinical entity, particularly if they follow the stricter diagnostic criteria. If your gastroenterologist is not addressing your concerns, an allergist/immunologist referral is appropriate.
Is MCAS the same as mastocytosis?
No. Mastocytosis involves abnormal proliferation (increased numbers) of mast cells, often with a detectable mutation (KIT D816V). MCAS involves normal or near-normal mast cell numbers that are hyperreactive and degranulate excessively. The symptoms can overlap, but the underlying pathology and diagnostic workup differ. Mastocytosis is typically diagnosed through bone marrow biopsy.
â ī¸This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.